Cytokine gene polymorphism [tumor necrosis factor-alpha (-308), IL-10 (-1082), IL-6 (-174), IL-17F, 1RaVNTR] in pediatric patients with primary immune thrombocytopenia and response to different treatment modalities

Blood Coagul Fibrinolysis. 2016 Apr;27(3):313-23. doi: 10.1097/MBC.0000000000000431.

Abstract

To evaluate the association between development, progression, and response to therapy among patients with immune thrombocytopenia (ITP) and different cytokine gene polymorphisms known to be related to autoimmunity [tumor necrosis factor (TNF)-alpha, interleukin (IL)-10, IL-6, IL-17, IL-1Ra]. A total of 50 pediatric patients with ITP (20 newly diagnosed, 30 chronic) and 50 healthy controls were investigated via PCR-restriction fragment length polymorphism analysis for cytokine gene polymorphism. Compared with controls, all patients showed a higher frequency of IL-6-174 CC [P = 0.0001, odds ratio (OR) = 7.048, 95% confidence interval (CI) = 2.18-22.7], higher GA genotype of TNF-α (-308) (P = 0.001, OR = 6.469, 95% CI = 2.0-20.9), higher CC genotype of IL-17F (P = 0.0001, OR = 55.545, 95% CI = 14.4-213.2), higher GG of IL-10-1082 (P = 0.029, OR = 3.6, 95% CI = 1.08-12.18), and A1A2 genotype of IL-1Ra (P = 0.039, OR = 2.374, 95% CI = 1.03-5.4). IL-10 GA and IL-1Ra A1A1 genotypes were higher among chronic patients (P = 0.042, P = 0.001 respectively) compared with newly diagnosed ones. Best platelet response to steroid treatment was found among GC genotype of IL-6 (-174) and GG genotype of IL-10 (-1082) in all patients with ITP. This suggests that previously mentioned cytokine gene polymorphisms possibly contribute to the susceptibility of acquisition of childhood ITP. Furthermore, GA genotype of IL-10 and A1A1 genotype of IL-1Ra polymorphisms are associated with increased risk of chronic ITP. IL-6 (-174) and IL-10 (-1082) genes might play a role in the effectiveness of steroid therapy among patients with ITP.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / genetics*
  • Interleukin-10 / genetics*
  • Interleukin-17 / genetics*
  • Interleukin-6 / genetics*
  • Male
  • Polymorphism, Genetic
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Purpura, Thrombocytopenic, Idiopathic / genetics
  • Steroids / therapeutic use*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / genetics*

Substances

  • IL10 protein, human
  • IL17F protein, human
  • IL6 protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-17
  • Interleukin-6
  • Steroids
  • Tumor Necrosis Factor-alpha
  • Interleukin-10